低分子肝素预防晚期卧床肿瘤患者深静脉血栓的临床应用价值

Clinical Application Value of Low Molecular Weight Heparin in Preventing Deep Vein Thrombosis in Patients with Advanced Bedridden Tumors

目的探讨晚期肿瘤卧床患者深静脉血栓预防中低分子肝素的价值。方法回顾性分析2020年1月—2021年12月太仓市第一人民医院肿瘤内科晚期卧床肿瘤60例患者的临床资料,依据深静脉血栓预防方法分为低分子肝素组、巴曲酶预防组,各30例。统计分析两组深静脉血栓发生情况、实验室指标、日常生活能力、不良反应发生情况、治疗满意度。结果低分子肝素组深静脉血栓发生率3.33%低于巴曲酶预防组26.67%,差异有统计学意义(χ^(2)=4.706,P<0.05)。用药后,低分子肝素组血小板计数、纤维蛋白原定量、D-二聚体水平低于巴曲酶预防组,凝血酶原时间及活化部分凝血活酶时间长于巴曲酶预防组,血红蛋白水平及MBI评分高于巴曲酶预防组,差异有统计学意义(P<0.05)。低分子肝素组的不良反应总发生率6.67%低于巴曲酶预防组的26.67%,差异有统计学意义(χ^(2)=4.320,P<0.05)。低分子肝素组治疗满意度86.67%高于巴曲酶预防组的63.33%,差异有统计学意义(P<0.05)。结论晚期肿瘤卧床患者深静脉血栓预防中低分子肝素的价值较常规性预防高。

Objective To investigate the value of low molecular weight heparin in prevention of deep vein thrombosis in patients with advanced bedridden tumor.Methods Retrospective analysis of clinical data from 60 late stage bedridden tumor patients in the Department of Oncology,Taicang First People′s Hospital from January 2020 to December 2021 were divided into low molecular weight heparin group and batroxobin prevention group according to the method of deep vein thrombosis prevention,with 30 patients in each group.The incidence of deep vein thrombosis,laboratory indicators,daily living ability,adverse reactions and treatment satisfaction of the two groups were statistically analyzed.Results The incidence of deep vein thrombosis in low molecular weight heparin group was 3.33%lower than that in batroxobin prevention group(26.67%),the difference was statistically significant(χ^(2 )=4.706,P<0.05).After medication,the platelet count,fibrinogen quantification,and D-dimer levels in the low molecular weight heparin group were lower than those in the batroxobin prevention group,while the prothrombin time and activated partial thromboplastin time were longer than those in the batroxobin prevention group,the hemoglobin level and MBI score were higher than those in the batroxobin prevention group,the difference was statistically significant(P<0.05).The total incidence of adverse reactions was 6.67%in the low molecular weight heparin group lower than 26.67%in the batroxobin prevention group,the difference was statistically significant(χ^(2 )=4.320,P<0.05).The treatment satisfaction rate of 86.67%in the low molecular weight heparin group was higher than 63.33%in the batroxobin prevention group,the difference was statistically significant(P<0.05).Conclusion The value of low molecular weight heparin in prevention of deep vein thrombosis in patients with advanced tumor bed is higher than that of conventional prophylaxis.